Translocation-associated renal cell carcinomas (RCCs) have been extensively subcharacterized in recent years, such that each is largely recognized by the 2016 World Health Organization as categorical neoplastic entities in the genitourinary tract. Those belonging to the t(6;11) family of tumors classically have a fusion between TFEB and MALAT1/α, and display a particular histomorphology. Specifically, they show a biphasic population of both small and large epithelioid cells, the smaller component of which surrounds basement membrane-type material. Despite this apt description, the tumors have variable morphology and mimic other RCCs including those with TFE3 translocations. Therefore, a high degree of suspicion is required to make the correct diagnosis.
Methods
The 2 cases described in this article were of strikingly different appearance, and initially considered consistent with other non-translocation–associated renal tumors. These included clear cell RCC (CCRCC), perivascular epithelioid cell tumor (PEComa), and other eosinophilic RCCs (mainly papillary RCC type 2).
Results
Using RNA sequencing techniques, they were found to harbor distinct pathogenic rearrangements involving the TFEB gene, namely, fusions with CLTC and NEAT1 (the latter partnering heretofore never reported).
Conclusions
These alterations manifested in 2 notably dissimilar lesions, underscoring the importance of including this family of carcinomas in the differential of any renal neoplasm that does not display immunophenotypic characteristics consistent with its morphology.
RickettsCJDe CubasAAFanH, et al. The Cancer Genome Atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep. 2018;23:313-326.e5.
2.
MochHReuterVE. WHO Classification of Tumours of the Urinary System and Male Genital Organs. International Agency for Research on Cancer; 2016.
3.
XiaQYWangXTFangR, et al. Clinicopathologic and molecular analysis of the TFEB fusion variant reveals new members of TFEB translocation renal cell carcinomas (RCCs): expanding the genomic spectrum. Am J Surg Pathol. 2020;44:477-489.
EvenepoelLPapathomasTGKrolN, et al. Toward an improved definition of the genetic and tumor spectrum associated with SDH germ-line mutations. Genet Med. 2015;17:610-620.
6.
McEvoyCRKoeLChoongDY, et al. SDH-deficient renal cell carcinoma associated with biallelic mutation in succinate dehydrogenase A: comprehensive genetic profiling and its relation to therapy response. NPJ Precis Oncol. 2018;2:9.
7.
DiNataleRGGorelickANMakarovV, et al. Putative drivers of aggressiveness in TCEB1-mutant renal cell carcinoma: an emerging entity with variable clinical course. Eur Urol Focus. Published December 6, 2019. doi:10.1016/j.euf.2019.11.013
8.
GutschnerTHämmerleMDiederichsS. MALAT1—a paradigm for long noncoding RNA function in cancer. J Mol Med (Berl). 2013;91:791-801.
9.
ArganiPZhongMReuterVE, et al. TFE3-fusion variant analysis defines specific clinicopathologic associations among Xp11 translocation cancers. Am J Surg Pathol. 2016;40:723-737.
10.
XiaQWangXYeS, et al. Novel gene fusion of PRCC-MITF defines a new member of MiT family translocation renal cell carcinoma: clinicopathological analysis and detection of the gene fusion by RNA sequencing and FISH. Histopathology. 2018;72:786-794.
11.
GuptaSArganiPJungbluthAA, et al. TFEB expression profiling in renal cell carcinomas: clinicopathologic correlations. Am J Surg Pathol. 2019;43:1445-1461.
12.
CaliòABrunelliMSegalaD, et al. VEGFA amplification/increased gene copy number and VEGFA MRNA expression in renal cell carcinoma with TFEB gene alterations. Mod Pathol. 2018;32:258-268.
13.
InamurK. Translocation renal cell carcinoma: an update on clinicopathological and molecular features. Cancers (Basel). 2017;9:111.
14.
Cancer Genome Atlas Research Network; LinehanWMSpellmanPT, et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med. 2016;374:135-145.
15.
CaliòABrunelliMSegalaD, et al. T(6;11) renal cell carcinoma: a study of seven cases including two with aggressive behavior, and utility of CD68 (PG-M1) in the differential diagnosis with pure epithelioid PEComa/epithelioid angiomyolipoma. Mod Pathol. 2017;31:474-487.
16.
RaoQLiuLChengL, et al. Renal cell carcinomas with t(6;11)(p21;q12): a clinicopathologic study emphasizing unusual morphology, novel alpha-TFEB gene fusion point, immunobiomarkers, and ultrastructural features, as well as detection of the gene fusion by fluorescence in situ hybridization. Am J Surg Pathol. 2012;36:1327-1338.
17.
InamuraKFujiwaraMTogashiY, et al. Diverse fusion patterns and heterogeneous clinicopathologic features of renal cell carcinoma with t(6;11) translocation. Am J Surg Pathol. 2012;36:35-42.
18.
LiuLQianJSinghHMeiersIZhouXBostwickDG. Immunohistochemical analysis of chromophobe renal cell carcinoma, renal oncocytoma, and clear cell carcinoma: an optimal and practical panel for differential diagnosis. Arch Pathol Lab Med. 2007;131:1290-1297.
19.
ArganiPLaéMHutchinsonB, et al. Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR. Am J Surg Pathol. 2005;29:230-240.
20.
SmithNEIlleiPBAllafM, et al. t(6;11) renal cell carcinoma (RCC): expanded immunohistochemical profile emphasizing novel RCC markers and report of 10 new genetically confirmed cases. Am J Surg Pathol. 2014;38:604-614.
21.
HaasBJDobinAStranskyN, et al. STAR-fusion: fast and accurate fusion transcript detection from RNA-Seq. bioRxiv. Published online March 24, 2017. doi:10.1101/120295
ArganiP. MiT family translocation renal cell carcinoma. Semin Diagn Pathol. 2015;32:103-113.
24.
PariharATickooSKKumarSAroraVK. Xp11 translocation renal cell carcinoma morphologically mimicking clear cell–papillary renal cell carcinoma in an adult patient: report of a case expanding the morphologic spectrum of Xp11 translocation renal cell carcinomas. Int J Surg Pathol. 2015;23:234-237.
25.
KauffmanECRickettsCJRais-BahramiS, et al. Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers. Nat Rev Urol. 2014;11:465-475.
26.
LynchMRTranMTRaltoKM, et al. TFEB-driven lysosomal biogenesis is pivotal for PGC1α-dependent renal stress resistance. JCI Insight. 2019;5:e126749.
27.
KuiperRPSchepensMThijssenJ, et al. Upregulation of the transcription factor TFEB in t(6;11)(p21;q13)-positive renal cell carcinomas due to promoter substitution. Hum Mol Genet. 2003;12:1661-1669.
28.
ChangIWHwangHYSungMT. Melanotic Xp11 translocation renal cancer: a case with PSF-TFE3 gene fusion and up-regulation of melanogenetic transcripts. Am J Surg Pathol. 2009;33:1894-1901.
29.
WilliamsonSRGrignonDJChengL, et al. Renal cell carcinoma with chromosome 6p amplification including the TFEB gene: a novel mechanism of tumor pathogenesis?Am J Surg Pathol. 2017;41:287-298.
30.
ArganiPReuterVEZhangL, et al. TFEB-amplified renal cell carcinomas: an aggressive molecular subset demonstrating variable melanocytic marker expression and morphologic heterogeneity. Am J Surg Pathol. 2016;40:1484-1495. doi:10.1097/pas.0000000000000720
31.
ArganiPAulmannSIlleiPB, et al. A distinctive subset of PEComas harbors TFE3 gene fusions. Am J Surg Pathol. 2010;34:1395-1406.
32.
MalinowskaIKwiatkowskiDJWeissSMartignoniGNettoGArganiP. Perivascular epithelioid cell tumors (PEComas) harboring TFE3 gene rearrangements lack the TSC2 alterations characteristic of conventional PEComas: further evidence for a biological distinction. Am J Surg Pathol. 2012;36:783-784.
33.
ChoHChungDHKhuranaHZhaiQJRoJY. The role of TFE3 in PEComa. Histopathology. 2008;53:236-249.
34.
ShenQRaoQXiaQY, et al. Perivascular epithelioid cell tumor (PEComa) with TFE3 gene rearrangement: clinicopathological, immunohistochemical, and molecular features. Virchows Arch. 2014;465:607-613.
35.
WangXTXiaQYYeSB, et al. RNA sequencing of Xp11 translocation-associated cancers reveals novel gene fusions and distinctive clinicopathologic correlations. Mod Pathol. 2018;31:1346-1360.
36.
JustPALetourneurFPouliquenC, et al. Identification by FFPE RNA-Seq of a new recurrent inversion leading ToRBM10-TFE3 fusion in renal cell carcinoma with subtle TFE3 break-apart FISH pattern. Genes Chromosomes Cancer. 2016;55:541-548.
37.
HodgeJCPearceKEWangXWiktorAEOliveiraAMGreippPT. Molecular cytogenetic analysis for TFE3 rearrangement in Xp11.2 renal cell carcinoma and alveolar soft part sarcoma: validation and clinical experience with 75 cases. Mod Pathol. 2013;27:113-127.
38.
RaoQShenQXiaQY, et al. PSF/SFPQ is a very common gene fusion partner in TFE3 rearrangement–associated perivascular epithelioid cell tumors (PEComas) and melanotic Xp11 translocation renal cancers: clinicopathologic, immunohistochemical, and molecular characteristics suggesting classification as a distinct entity. Am J Surg Pathol. 2015;39:1181-1196.
39.
ArganiPLuiMYCouturierJ, et al. A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17)(p11.2;q23). Oncogene. 2003;22:5374-5378.
40.
ParillaMKadriSPatilS, et al. Are sporadic eosinophilic solid and cystic renal cell carcinomas characterized by somatic tuberous sclerosis gene mutations?Am J Surg Pathol. 2018;42:911-917.
41.
TjotaMChenHParillaMWanjariPSegalJAnticT. Eosinophilic renal cell tumors with a TSC and MTOR gene mutations are morphologically and immunohistochemically heterogenous: clinicopathologic and molecular study. Am J Surg Pathol. 2020;44:943-954.
42.
ChenYBMirsadraeiLJayakumaranG, et al. Somatic mutations of TSC2 or MTOR characterize a morphologically distinct subset of sporadic renal cell carcinoma with eosinophilic and vacuolated cytoplasm. Am J Surg Pathol. 2019;43:121-131.
43.
NingLLiZWeiDChenHYangC. LncRNA, NEAT1 is a prognosis biomarker and regulates cancer progression via epithelial-mesenchymal transition in clear cell renal cell carcinoma. Cancer Biomark. 2017;19:75-83.
44.
PeiJCooperHFliederDB, et al. NEAT1-TFE3 and KAT6A-TFE3 renal cell carcinomas, new members of MiT family translocation renal cell carcinoma. Mod Pathol. 2019;32:710-716.
45.
ArganiPYonescuRMorsbergerL, et al. Molecular confirmation of t(6;11)(p21;q12) renal cell carcinoma in archival paraffin-embedded material using a break-apart TFEB FISH assay expands its clinicopathologic spectrum. Am J Surg Pathol. 2012;36:1516-1526.
46.
TrpkovKHesOBonertM, et al. Eosinophilic, solid, and cystic renal cell carcinoma clinicopathologic study of 16 unique, sporadic neoplasms occurring in women. Am J Surg Pathol. 2016;40:60-71.
47.
MendelLAmbrosettiDBodokhY, et al. Comprehensive study of three novel cases of TFEB-amplified renal cell carcinoma and review of the literature: evidence for a specific entity with poor outcome. Genes Chromosomes Cancer. 2018;57:99-113.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
